ACEBROPHYLLINE

Product Short Description

Status: Commercial
Route of Administration: Oral
Dosage Forms: Capsules, Syrup
Regulatory Documents: DMF, WC, KFDA, COFEPRIS
Use: Human
Manufacturing Site: INDIA
CAS NO: 96989-76-3
Categories: Antiasthamatic

Products Description

Mechanism of Action: Acebrophylline modifies mucus secretion by lowering viscosity of ‘gel’ phase, increasing ‘sol’ phase and increases mucociliary clearance by augmenting ciliary motility. Acebrophylline inhibits intracellular phosphodiesterase and facilitates bronchial muscles relaxation by increasing cAMP levels.

Drug Indications: It is a bronchodilator indicated in the symptomatic treatment of bronchopulmonary disorders associated with bronchospasm.

Disclaimer:
1) Patent related content
2) Information is available from Public Source only